The Effect of Renin Angiotensin System Genetic Variants in Acute Pancreatitis by Skipworth, JRA et al.
The Effect of Renin Angiotensin System Genetic Variants in 
Acute Pancreatitis
RA Skipworth James1,2,3, M Nijmeijer Rian4, C van Santvoort Hjalmar10, GH Besselink 
Marc5, Schulz Hans-Ulrich6, Kivimaki Mika7, Kumari Meena7, A Cooper Jackie8, Acharya 
Jay8, Shankar Arjun2, Malago’ Massimo1,2, E Humphries Steve8, WM Olde Damink 
Steven1,2,9, and E Montgomery Hugh1,3
1Department of Surgery and Interventional Science, University College London, London, UK 
2Department of Hepatopancreaticobiliary Surgery, Royal Free Hospital NHS Trust, London, UK 
3UCL Institute of Human Health & Performance, University College London, London, UK 
4Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands 5Department of 
Surgery, Academic Medical Center, Amsterdam, the Netherlands 6General Surgery Department, 
Medical Faculty of Otto-von-Guericke University, Magdeburg, Germany 7Department of 
Epidemiology and Public Health, University College London, 1–19 Torrington Place, London, UK 
8Centre for Cardiovascular Genetics, University College London, London 9Department of Surgery, 
Correspondence & Reprint Requests: Mr J Skipworth, Department of Surgery & Interventional Science, 74 Huntley Street, University 
College London, London, WC1E 6AU; jamesskipworth@doctors.org.uk. 
Author Contributions
Study 
Concept 
& 
Design
Data Acquisition Data Analysis 
& 
Interpretation
Manuscript Drafting Critical 
Revision of 
Manuscript
Statistical Analysis Funding Admin or 
Technical 
Support
Skipworth J X X X X X X X X
Nijmeijer R X X X X X
van Santvoort H X X X X X
Besselink M X X X X X
Schulz H-U X X X X X
Cooper J X X X X X
Acharya J X X X X
Kivimaki M X X X X
Kumari M X X X X
Shankar A X X X X
Malago’ M X X X X X
Humphries S X X X X X
Olde Damink S X X X X X
Montgomery H X X X X X X X
All authors read and approved the final manuscript. All authors declare that they have no competing interests.
NIH Public Access
Author Manuscript
Ann Surg. Author manuscript; available in PMC 2016 January 01.
Published in final edited form as:
Ann Surg. 2015 January ; 261(1): 180–188. doi:10.1097/SLA.0000000000000655.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Maastricht University Medical Centre, Maastricht, Netherlands 10Department of Surgery, 
University Medical Center Utrecht, Utrecht, Netherlands
Abstract
Objectives—We sought association of genetic variants in the renin angiotensin system (RAS) 
and Vitamin D system with acute pancreatitis (AP) development and severity.
Summary Background Data—The endocrine RAS is involved in circulatory homeostasis 
through the pressor action of angiotensin II (ang II) at its AT1 receptor (AT1R). However, local 
RAS regulate growth and inflammation in diverse cells and tissues, and their activity may be 
suppressed by Vitamin D. Intra-pancreatic ang II generation has been implicated in the 
development of AP.
Methods—Five hundred and forty-four Caucasian AP patients from three countries (UK 22; 
Germany 136; Netherlands 386) and 8487 control subjects (UK 7833, Netherlands 717) were 
genotyped for eight polymorphisms of the RAS/vitamin D systems, chosen based on likely 
functionality.
Results—The ACE I (rather than D) allele was significantly associated with alcohol-related AP 
when all cohorts were combined (p=0.03). The Renin rs5707 G (rather than A) allele was 
associated with AP (p=0.002), infected necrosis (p=0.025) and mortality (p=0.046).
Conclusions—The association of two RAS polymorphisms with AP suggests the need for 
further detailed analysis of the role of RAS/Vitamin D in the genesis or severity of AP, 
particularly given the ready potential for pharmacological manipulation of this system using 
existing marketed agents. However, further replication studies will be required before any such 
association is considered robust, particularly given the significant heterogeneity of AP causation 
and clinical course.
Keywords
Pancreatitis; RAS; ACE; Genetics
Introduction
Acute pancreatitis (AP) is a common inflammatory disorder that is mild and self-limiting in 
80% of cases but which, when severe, may necessitate intensive care admission and lead to 
organ failure and death. The majority of cases are secondary to either gallstones or alcohol, 
although a multitude of causes exist. It is a common disease (current UK incidence: 150–420 
cases per million per annum) and increasingly prevalent.1 However, despite recent 
improvements in intensive care unit management and techniques of organ support, the 
severity and mortality associated with AP has not decreased since the 1970s1: up to 25% of 
patients will be diagnosed with severe disease2–5 and approximately 4% of all patients will 
die.6,7 This can be partly explained by the fact that no specific prophylactic or therapeutic 
agent is available, and current management is largely supportive. Better understanding of the 
molecular drivers of AP is essential for the identification of new therapeutic strategies. 
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Single-nucleotide polymorphisms (SNPs) are single base-pair variants in the DNA sequence 
which occur with a population frequency of >1%. Associated biological impacts may result- 
for instance, if the SNP alters an amino acid in the protein transcribed (thus affecting 
protein structure and function), or if the SNP lies in a region which affects gene 
transcription or mRNA stability. Associating such functional variants with specific disease 
phenotypes is thus one means by which to infer a causal role for the gene product in disease 
pathogenesis. Gene-association studies, performed to assess the molecular drivers of 
pancreatitis (Table 1), have generally focussed on the activation of pancreatic enzymes and 
pro-enzymes (one of the key steps in the initiation and propagation of pancreatic 
inflammation) or the process of systemic inflammation secondary to acute pancreatitis. 
However, small cohorts have weakened the ability to detect associations in mixed patient 
groups.
The renin-angiotensin system (RAS), originally described as a key regulator of intravascular 
homeostasis, controlling extracellular fluid volume and blood pressure,18 represents a 
potential target of such gene-association studies. In response to decreased afferent arteriolar 
pressure, decreased filtered sodium load or sympathetic nervous stimulation, the renal 
juxtaglomerular apparatus releases renin,19 which cleaves hepatically-derived 
angiotensinogen20 to yield angiotensin I (ang I). Angiotensin-converting-enzyme (ACE) 
subsequently hydrolyses ang I to yield the effector peptide angiotensin II (ang II)21, whose 
effects are mediated through 2 specific human receptors: the angiotensin II type 1 and 2 
receptor (AT1R and AT2R).22 However, local renin-angiotensin systems are now known to 
exist in diverse cells and tissues, including the pancreas,23,24 where they have paracrine and 
autocrine roles in the regulation of metabolism, blood flow, inflammation and healing.25–27
Within the pancreas, local generation of ang II influences exocrine and endocrine function 
through activation of the AT1R, stimulating increases in pancreatic enzyme secretion28,29, 
while reducing islet blood flow and delaying insulin release.30–32 It is also implicated in the 
initiation and propagation of AP. Increased expression of RAS components is identified in 
experimental models of AP,33,34 where they drive activation of monocytes and 
macrophages,35,36 and expression of pro-inflammatory molecules such as interleukin-6 
(IL-6), nuclear factor-κβ (NF-κβ) and monocyte chemoattractant protein-1 (MCP-1).37 Such 
pro-inflammatory effects may occur through a number of possible AT1R-mediated 
mechanisms including generation of reactive oxygen species, matrix metallopeptidase-9 
(MMP-9), nicotinamide adenine dinucleotide phosphate (NADPH), NF-κβ, tumour growth 
factors (TGFs) and Smad, as well as activation of human pancreatic stellate cells.37–42 RAS 
inhibition has also been shown to attenuate the expression of pro-inflammatory molecules 
and mitigate pancreatic cellular injury.43,44 Further, vitamin D may influence RAS activity 
by suppressing renin synthesis at the transcriptional level, thus acting as a negative regulator 
of the RAS.45–49
The association of AP (and its severity) with specific variants in key RAS/Vitamin D 
pathway genes would infer a causal role for such systems in AP pathogenesis. Given the 
postulated role for RAS/Vit D in AP pathogenesis, we hypothesized that such gene 
associations would be identified. We thus sought association of common functional variants 
in the RAS and Vitamin D systems with AP, and its severity, in order to clarify the possible 
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role for RAS in AP pathogenesis; and in particular to elucidate whether genotypes 
associated with higher RAS activity were associated with the development or severity of 
acute pancreatitis.
Methods
Subjects
Blood samples were taken from AP patients from 3 Northern European countries, following 
local ethical approval (The Joint UCL/UCLH Committees on the Ethics of Human Research 
(Committee A); Reference No. 08/H0714/90) and written informed consent: (i) University 
College London Hospitals (UCLH, London, UK), between 2006 and 2009; (ii) Magdeburg 
University Hospital (Magdeburg, Germany) between 1996 and 2003; (iii) Eight university 
medical centres and seven major teaching hospitals in the Netherlands between 2004 and 
2007, with blood stored at University Medical Centre Utrecht (Utrecht, Netherlands), as part 
of the PROPATRIA trial, a multicenter, randomized controlled trial (trial registry number 
ISRCTN38327949).50
AP was defined as upper abdominal pain in combination with serum amylase or lipase 
concentrations raised to at least three times the upper limit of normal. Prospective data, 
including demographics, predicted severity score (e.g. acute physiology and chronic health 
evaluation II (APACHE II)), necrosis and in-hospital mortality, were collected. Patients 
were classified as having actual (rather than predicted) severe AP in the presence of organ 
failure of over 48 hours duration and/or local pancreatic or peri-pancreatic complications 
such as necrosis, fluid collections and pseudocysts (as defined by the revised Atlanta 
classification51).
Controls were 2766 (2711 following quality control) healthy UK Caucasian males who had 
participated in the second Northwick Park Heart Study (NPHSII) (aged 51 to 60 years, 
recruited from 9 general medical practices within the UK) for assessment of ACE 
(rs4646996) and CYP2R1 (rs10741657) genotypes, and 5059 (1334 women and 3725 men) 
UK civil servants from the Whitehall II study (WHII; aged 35–55 years and working in the 
London offices of 20 Whitehall departments)52 for analysis of other genetic variants. Full 
details of the genotyping and quality control have been published previously.53 In summary, 
DNA from WHII was extracted from 6156 individuals from whole blood samples using 
magnetic bead technology (Medical Solutions, Nottingham, UK) and normalised to a 
concentration of 50ng/μl. Custom SNP arrays were designed by the Institute of Translational 
Medicine and Therapeutics, the Broad Institute and the National Heart Lung and Blood 
Institute supported Candidate-gene Association Resource Consortium (HumanCVD 
BeadChip)54 on 5592 of these samples. After restriction to White/European groups and 
quality control, 5059 samples were utilised for analysis. Seven hundred and seventeen 
samples were also obtained from blood-bank donors within the Netherlands and utilised as 
controls for all genotypes (kindly provided by Prof. C. Wijmenga, Department of Genetics, 
University Medical Center Groningen, Groningen, the Netherlands.
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Genetic Analysis
DNA was extracted from UK subjects utilising the ‘salting-out’ technique55; from German 
subjects using Qiagen® DNA extraction kits (Qiagen, Hilden, Germany); and using the 
DNA isolation kit I from the Magna Pure LC (Roche Diagnostics, Indianapolis, USA) for 
the Dutch cohort. Common functional polymorphisms in genes of the human RAS and 
Vitamin D systems, or those previously associated with pancreatic disease, were selected by 
review of the published literature (Table 2). Subjects were genotyped for all pre-selected 
variants, with genetic analysis performed at University College London (London, UK).
DNA was measured and standardised using a Nanodrop® 8000 (Thermo Scientific; 
Waltham, Ma, USA) spectrophotometer and Beckman Coulter Biomek® 2000 (Biodirect; 
Taunton, Ma, USA) respectively, to a concentration of 15ng/μl stock, prior to further 
dilution to 5ng/μl working stocks. The ACE insertion/deletion polymorphism was assessed 
via initial PCR amplification of DNA and subsequent identification of differences in DNA 
size utilising 7.5% microplate array diagonal gel electrophoresis (MADGE). The remaining 
genotypes were determined by polymerase chain reaction amplification (PCR), utilising 
custom-prepared TaqMan® SNP genotyping assay kits (Applied Biosystems; Carlsbad, CA, 
USA).
Statistical Analysis
Patient data were anonymised. Allele frequencies were tested for deviation from Hardy-
Weinberg equilibrium using a χ2 goodness-of-fit test and all allele frequencies were in 
keeping with existing published population data. Odds ratios and p values were calculated 
for an additive genetic effect using logistic regression models with adjustment for age, sex 
and region. For ACE and rs5707 genotypes we also tested the recessive model. Analysis was 
performed using Stata Version 11 (StataCorp, Texas, USA) and a p value of < 0.05 was 
considered statistically significant. No adjustment was made for multiple comparisons. 
Power calculations were performed using Quanto (http://hydra.usc.edu/gxe/). Detectable 
odds ratios were calculated for the sample size of 544 cases assuming an additive effect. In 
addition we calculated the number of AP cases that would be required to detect an effect of 
the size observed in this study. The ratio of controls to cases was 5.4 for (rs4646996) and 
CYP2R1 (rs10741657), 1.4 for AT2R (rs1403543) and AGT (rs699) and 10.6 for the 
remaining SNPs.
Results
Combined study groups (Table 3)
Five hundred and forty-four Caucasian patients (304 [55.9%] male) with acute pancreatitis 
(UK n=22, Germany n=136, Netherlands n=386), and 8487 control subjects (UK NPHS-II 
n=2711, UK WHII n=5059, Netherlands n=717) were genotyped. Median patient age was 
56 years (17–91years). Two hundred and sixty nine (49.5%) cases were secondary to biliary 
disease, 118 (21.7%) to alcohol and 157 (28.9%) to other causes. One hundred and seventy 
three (31.8%) patients overall had severe acute pancreatitis (based upon revised Atlanta 
criteria51; UK n=4, Germany n=65, Netherlands n=104) and 38 (7.0%) died (Germany n=18 
and Netherlands n=20). Infected necrosis occurred in 58 (14.2%) patients in UK and Dutch 
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cohorts (UK n=2 and Netherlands n=56). Data on infected necrosis were not available in the 
German cohort. Genotype distributions for cases and controls are shown in Table 4 for the 
overall cohort. The G allele of the renin rs5707 SNP was associated with AP (p=0.003), 
infected necrosis (p=0.02) and mortality (p=0.003) in the Dutch cohort, where 60% of 
deaths occurred secondary to infected necrosis (Table 5). These findings were replicated 
when the cohorts were combined (AP (OR (95% CI) = 2.19 (1.34–3.60) p=0.002), infected 
necrosis (2.75 (1.13–6.68) p=0.025) and mortality (2.66 (1.02–6.95) p=0.046) for the 
recessive model).
There were no other significant genotype associations with the development of AP, severe 
AP or mortality from AP.
Alcohol-related acute pancreatitis
One hundred and eighteen patients (21.7% of total) had alcohol-related AP (9 UK, 37 
Germany, 72 Netherlands). Median age was 47 years (22–88 years) and 98 (83.1%) were 
male. Of Dutch and UK patients, 11 (14.1%) had infected necrosis (10 Dutch). Fifty (42.4%) 
patients had actual severe pancreatitis (1 UK, 28 Germany, 21 Dutch), and five (4.2%) died 
(3 Germany, 2 Netherlands). The ACE I (rather than D) allele (rs4646994) was associated 
with alcohol-related AP when the cohorts were combined (OR (95% CI) 0.57 (0.34–0.95) 
p=0.03 recessive model for DD vs. II/ID). There were no other significant associations 
(Table 6).
Biliary acute pancreatitis
Two hundred and seventy patients had biliary AP (49.4% of total: 8 UK, 53 Germany, 209 
Netherlands). Median age was 62 years (18–91 years) and 115 (42.6%) patients were male. 
Of Dutch and UK subjects, 26 (12.1%) patients developed infected necrosis (25 Dutch, 
1UK). Seventy (25.9%) had actual severe AP (2 UK, 19 Germany, 49 Netherlands) and 17 
(6.3%) died (8 Germany, 9 Netherlands). No significant associations with genotype were 
identified (Table 7).
Discussion
To our knowledge, this is the largest study thus far investigating the association of RAS 
genotype with acute pancreatitis. The human ACE gene has a genetic variant in which the 
absence (Deletion, D allele) rather than the presence (Insertion, I allele) of a 287 base pair 
fragment is associated with higher circulating65 and tissue ACE activity such as that in 
myocardium,66 and inflammatory cells.67 Our analysis of 544 AP patients and 8487 controls 
demonstrated an association of the ACE I allele (lower ACE activity) with alcohol-related 
acute pancreatitis. To date, no other studies have identified an association of ACE genotype 
with the development or severity of acute,68 chronic,69–72 familial70 or tropical calcific 
pancreatitis.73 However, these studies were small, incorporated mixed aetiologies and 
disease-types (acute, chronic, familial and tropical calcific pancreatitis), and did not address 
other RAS variants (see Table 8). We sought to resolve these issues by using larger sample 
sizes; the comparison of single aetiologies; the investigation of the effects of multiple RAS 
genotypes; investigation of alternate systems that may affect the RAS pathway (e.g. the 
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vitamin D pathway); and use of multiple cohorts. However, still larger sample sizes may be 
required to detect effect sizes of the magnitude found (see Table 4) as the sample size 
utilised here only had sufficient power to detect an odds ratio in the range of 1.20–1.26.
Alcohol has also been shown to directly activate RAS in animal models of alcoholic 
cardiomyopathy.74 Despite this, our study demonstrated an association of the ACE I allele 
(lower ACE activity) rather than the postulated D-allele (i.e. high activity) with alcohol-
related acute pancreatitis. This finding seems contrary to the hypothesis that increasing 
activity of the RAS may lead to increasing likelihood of developing acute pancreatitis or 
severe disease. However, ACE inhibitor use has been associated with pancreatitis,75 and 
multiple angiotensin I processing enzymes are now known to exist (e.g. chymase, 
chymotrypsin, tonin, aminopeptidase A, B and N, prolylendopeptidase, and neutral 
endopeptidase). Further, ACE 2, a homologue of ACE with 42% sequence homology76 has 
recently been discovered and its primary product, Ang (1–7), acts through the Mas 
receptor77 to negatively regulate the RAS; thereby counter-balancing ACE action. Thus, 
ACE levels, as assessed by RAS genotypes, may not truly represent overall RAS or ACE 
activity at a local or systemic level, and further studies may require serum assays or 
pancreatic biopsy samples for direct assessment of tissue ACE levels.
When the cohorts were combined, the renin rs5707 G allele was associated with AP 
(p=0.002), infected necrosis (p=0.025) and mortality (p=0.046). The renin rs5707 G allele 
has previously been associated with hypertension and diabetes, and has been hypothesised to 
increase the activity of the RAS.60 However, although this finding was also present in the 
Dutch cohort, we could not replicate this finding in cohorts from other countries. Nor was 
there biological consistency through disease association with other RAS genotypes, or those 
of (the putatively RAS-regulatory) Vitamin D system investigated here. Such lack of 
consistency and replication is likely to be secondary to heterogeneity in AP causation and 
allele frequencies between populations, as well as small individual cohort sample sizes, 
particularly when single aetiologies were examined. Similarly, the patient cohort contained 
a high proportion of Dutch and German individuals, whilst the control group was UK-
dominated. However, all cohorts were derived from North-European, Caucasian 
populations with similar ancestry and any minor allelic variations are therefore unlikely to 
influence the significance of results. Meanwhile, the medical systems and diagnostic criteria 
utilised in each country were similar, although any national differences in diagnosis, 
management and outcome would require analysis via long-term, prospective, national 
registries.
Although multiple causes exist, a common pathophysiological pathway in AP involves 
premature activation of various proteolytic pancreatic enzymes such as trypsin, 
chymotrypsin, carboxypeptidase and kallikrein. Chymotrypsin is capable of converting 
angiotensinogen to ang I, and trypsin to catalyse ang II to ang III and IV.78 Therefore, 
pancreatic enzyme activity may be another crucial factor in the activation of RAS during 
AP- an effect which may swamp that of RAS genotype. Further, the activation of this 
common AP-initiating pathway occurs via different mechanisms in biliary- and alcohol-
related pancreatitis, and the heterogeneous proportion of each in the three cohorts may 
further explain the inconsistency of genetic association between the cohorts from various 
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geographical regions (UK: 40.9% ETOH, 36.4% biliary, 22.7% other; Netherlands: 18.7% 
ETOH, 54.1% biliary, 27.2% other; Germany: 27.2% ETOH, 39.0% biliary, 33.8% other).
However, such data must be interpreted with caution, and cannot be taken as proof of a role 
for RAS or Vitamin D in the genesis or severity of AP, perhaps in part due to the study 
limitations, including the problem of multiple comparison and a relatively small sample size, 
but also possibly in part due to heterogeneity of AP causation and variations in clinical 
course. Adjustment for multiple comparison, whilst necessary, may also make the discarding 
of a ‘true positive’ finding more likely than that of a ‘false positive’. In addition, uniformity 
in assessment of disease severity is difficult to achieve,79 and heterogeneity, by its 
definition, will also weaken power in genetic studies. Further studies should concentrate on 
large, well-structured study cohorts with clear phenotypes and substantial numbers of 
individuals in any aetiological group, as well as with tight coconstraints on defined severity, 
in order to circumvent these issues. In addition, association of any phenotype with one 
allelic variant may, of course, occur by chance. In addition, the gene variant under study 
may (through strong linkage disequilibrium) mark activity in an adjacent gene (through 
which any observed associations are in fact mediated). For reasons such as this, findings of 
candidate gene association studies require replication if to be considered robust, with 
subsequent fine-mapping of the genes required.
Further studies should concentrate on large, well-structured study cohorts with clear 
phenotypes, to attempt to circumvent these issues. However, the association of two RAS 
polymorphisms ACE I and Renin rs5707 G ACE I with AP in this study does suggest that 
this issue warrants further detailed analysis, given the ready potential for pharmacological 
manipulation of this system using existing marketed agents. Such roles are also worthy of 
active investigation in diverse pancreatic disease states.
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Table 1
Selected recent genetic associations with various clinical forms of pancreatitis
Gene Protein No. Pts Association Authors
PRSS1 Cationic Trypsinogen 108 HCP; 415 ICP; 82 Controls CP Teich et al, 20028
SPINK1 Pancreatic Secretory Trypsin 
Inhibitor
1 32 CP; 117 Controls
2 198 Mixed CP; 290 
Controls
1 CP
2 Hereditary CP
Kaneko et al, 20019
Chandak et al, 200410
CFTR Cystic Fibrosis Transmembrane 
Regulator
1 67 ICP; 60 Controls
2 25 CP; 236 Controls
1 Idiopathic CP
2 CP
Weiss et al, 200511
Tzetis et al, 200712
CTLA-4 Cytotoxic T Lymphocyte-
Associated Antigen 4
46 AIP; 78 CCP; 200 Controls Autoimmune Pancreatitis Chang et al, 200713
IL-8 Interleukin-8 92 AP; 200 Controls Severity of AP Hofner et al, 200614
TGF-β1 Transforming Growth Factor β1 28 CP; 94 Controls Fibrosis in CP Bendicho et al, 200515
TLR-4 Toll-Like Receptor-4 521 AP; 120 Controls No association with AP Guenther et al, 201016
TNF-α Tumour Necrosis Factor α 77AP; 71 Controls AP Severity Balog et al, 200517
AP- Acute Pancreatitis; CP- Chronic Pancreatitis; AIP- Autoimmune Pancreatitis; HCP- Hereditary Chronic Pancreatitis; ICP- Idiopathic Chronic 
Pancreatitis; CCP- Chronic Calcific Pancreatitis
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Table 5b
Effect of Renin G allele upon outcome from acute pancreatitis in combined cohort samples and controls.
Rs5707 AA AC CC P value*
Controls 3476 (60.6) 2004 (35.0) 253 (4.4)
AP 314 (61.2) 159 (31.0) 40 (7.8)
OR (95% CI) 1.00 0.99 (0.77–1.27) 2.18 (1.32–3.61) 0.002
Infected Necrosis No 191 (60.3) 106 (33.4) 20 (6.3)
Yes 33 (63.5) 11 (21.2) 8 (15.4)
OR (95% CI) 1.00 0.61 (0.30–1.27) 2.37 (0.96–5.88) 0.025
Mortality No 290 (60.8) 153 (32.1) 34 (7.1)
Yes 24 (66.7) 6 (16.7) 6 (16.7)
OR (95% CI) 1.00 0.47 (0.19–1.19) 2.18 (0.82–5.80) 0.046
*
Recessive model
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Table 6
Comparison of genotype frequency between patients with AP secondary to alcohol and combined controls.
Gene P value*
ACE (rs4646994) II ID DD
Alcohol 32 (27.6) 65 (56.0) 19 (16.4) 0.18 (Additive Model)
Control1,3 839 (24.5) 1656 (48.4) 928 (27.1)
OR (95% CI) 1.00 1.17 (0.74–1.86) 0.63 (0.34–1.15) 0.03 (Recessive Model)
AT1 R (rs5186) AA AC CC
Alcohol 57 (50.9) 41 (36.6) 14 (12.5) 0.85
Control2,3 2778 (48.4) 2433 (42.4) 530 (9.2)
1.00 0.75 (0.49–1.16) 1.23 (0.65–2.33)
AT2 R (rs1403543) AA AG GG
Alcohol 46 (14.1) 10 (6.4) 45 (14.0) 0.79
Control3 280 (39.8) 146 (20.8) 277 (39.4)
1.00 1.17 (0.44–3.08) 0.94 (0.60–1.47)
CYP2R1 GG GA AA
(rs10741657)
Alcohol 34 (33.3) 47 (46.1) 21 (20.6) 0.18
Control1,3 1235 (37.1) 1576 (47.4) 517 (15.5)
1.00 1.16 (0.73–1.86) 1.52 (0.84–2.76)
AGT (rs699) AA AG GG
Alcohol 45 (40.2) 57 (50.9) 10 (8.9) 0.92
Control2,3 2104 (36.6) 2701 (47.0) 945 (16.4)
1.00 1.18 (0.78–1.81) 0.79 (0.38–1.64)
Renin (rs5707) AA AC CC
Alcohol 72 (64.9) 34 (30.6) 5 (4.5) 0.95
Control2,3 3476 (60.6) 2004 (35.0) 253 (4.4)
1.00 0.93 (0.60–1.45) 1.15 (0.43–3.10)
VDR (rs2228570) GG GA AA
Alcohol 34 (30.6) 60 (54.1) 17 (15.3) 0.17
Control3 293 (41.6) 304 (43.2) 107 (15.2)
1.00 1.76 (1.09–2.85) 1.30 (0.68–2.51)
GC (rs7041) CC CA AA
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Gene P value*
Alcohol 38 (34.2) 57 (51.4) 16 (14.4) 0.30
Control2,3 1752 (30.5) 2912 (50.7) 1075 (18.7)
1.00 0.87 (0.56–1.36) 0.72 (0.39–1.35)
1NPHSII;
2WHII;
3Netherlands Blood Bank
*Additive genetic model adjusted for age, sex, region.
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Table 7
Comparison of genotype frequency between patients with AP secondary to biliary pathology and combined 
controls.
Gene P value*
ACE (rs4646994) II ID DD
Biliary 72 (27.6) 125 (47.9) 64 (24.5) 0.48
Control1,3 839 (24.5) 1656 (48.4) 928 (27.1)
1.00 0.95 (0.66–1.37) 0.86 (0.56–1.31)
AT1 R (rs5186) AA AC CC
Biliary 123 (50.4) 95 (38.9) 26 (10.7) 0.16
Control2,3 2778 (48.4) 2433 (42.4) 530 (9.2)
1.00 0.76 (0.54–1.06) 0.80 (0.47–1.36)
AT2 R (rs1403543) AA AG GG
Biliary 97 (39.6) 74 (30.2) 74 (30.2) 0.14
Control3 280 (39.8) 146 (20.8) 277 (39.4)
1.00 0.76 (0.47–1.23) 0.76 (0.53–1.10)
CYP2R1 GG GA AA
(rs10741657)
Biliary 96 (41.4) 108 (46.6) 28 (12.1) 0.62
Control1,3 1235 (37.1) 1576 (47.4) 517 (15.5)
1.00 1.01 (0.72–1.42) 0.84 (0.50–1.41)
AGT (rs699) AA AG GG
Biliary 97 (39.4) 110 (44.7) 39 (15.9) 0.58
Control2,3 2104 (36.6) 2701 (47.0) 945 (16.4)
1.00 1.02 (0.73–1.43) 1.17 (0.73–1.88)
Renin (rs5707) AA AC CC
Biliary 161 (63.9) 71 (28.2) 20 (7.9) 0.59
Control2,3 3476 (60.6) 2004 (35.0) 253 (4.4)
1.00 0.79 (0.56–1.12) 2.11 (1.09–4.08)
VDR (rs2228570) GG GA AA
Biliary 96 (39.7) 109 (45.0) 37 (15.3) 0.60
Control3 293 (41.6) 304 (43.2) 107 (15.2)
1.00 1.02 (0.72–1.44) 1.16 (0.72–1.44)
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Gene P value*
GC (rs7041) CC CA AA
Biliary 78 (32.0) 121 (49.6) 45 (18.4) 0.36
Control2,3 1752 (30.5) 2912 (50.7) 1075 (18.7)
1.00 0.73 (0.51–1.04) 0.86 (0.54–1.38)
1NPHSII;
2WHII;
3Netherlands Blood Bank
*Additive genetic model adjusted for age, sex, region
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Table 8
Previous studies investigating the effect of RAS polymorphisms on outcome from pancreatitis
Gene; SNP Study Cohorts Significant Associations Authors
ACE; I/D 79 AP/95 Controls None Oruc et al, 200968
ACE; I/D 98 AP & 789 CP/1294 Controls None Hucl et al, 200969
ACE; I/D 104 CP + 51 FP/163 Controls None Oruc et al, 200470
ACE; I/D 55 CP/128 Controls None Lukic et al, 201172
ACE; I/D 91 TCP/99 Controls None Bhaskar et al, 200673
AP- Acute Pancreatitis; CP- Chronic Pancreatitis; AIP- Autoimmune Pancreatitis; HCP- Hereditary Chronic Pancreatitis; ICP- Idiopathic Chronic 
Pancreatitis; CCP- Chronic Calcific Pancreatitis
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